2020
DOI: 10.3389/fneur.2020.00081
|View full text |Cite
|
Sign up to set email alerts
|

Identification and Management of Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
46
0
23

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(81 citation statements)
references
References 92 publications
1
46
0
23
Order By: Relevance
“…[6][7][8] Medical treatments for PSH include combinations of µ-opioid receptor agonist (morphine), non-selective ß-receptor blocker (propranolol), α 2 -receptor agonist (clonidine), GABA-receptor agonist (gabapentin), dopaminereceptor antagonist (bromocriptine) and benzodiazepines (diazepam) to abort or minimize PSH episodes via inhibition of sympathetic flow, afferent sensory process and effector end organ response. [6][7][8][11][12][13][14] Early diagnosis and optimized treatment is believed to shorten ICU stay, facilitate patient recovery and minimize physical disability. In conclusion, 'clinical scoring' was used to dignose PSH, since there was no any confirmatory test.…”
Section: Discussionmentioning
confidence: 99%
“…[6][7][8] Medical treatments for PSH include combinations of µ-opioid receptor agonist (morphine), non-selective ß-receptor blocker (propranolol), α 2 -receptor agonist (clonidine), GABA-receptor agonist (gabapentin), dopaminereceptor antagonist (bromocriptine) and benzodiazepines (diazepam) to abort or minimize PSH episodes via inhibition of sympathetic flow, afferent sensory process and effector end organ response. [6][7][8][11][12][13][14] Early diagnosis and optimized treatment is believed to shorten ICU stay, facilitate patient recovery and minimize physical disability. In conclusion, 'clinical scoring' was used to dignose PSH, since there was no any confirmatory test.…”
Section: Discussionmentioning
confidence: 99%
“…TBI causes paroxysmal sympathetic hyperactivity (PSH) manifested by increases in sympathetic activity involved in heart rate, blood pressure, respiratory rate and other. PSH has been reported in 33 % patients suffering from severe TBI and associated with poorer outcome (16,17). Hypoxia and hypotension following TBI are recognized as a signifi cant secondary disorder associated with a poor outcome (18).…”
Section: Physiological Factorsmentioning
confidence: 99%
“…Both the onset and the duration of the episodes are variable, ranging from less than 2 weeks to many months; in some cases, residual dystonia and spasticity persist chronically after the sympathetic storms subside. Notably, PSH may clinically resemble other entities such as malignant catatonia or neuroleptic malignant syndrome and may share triggers such as neuroleptic agents [15]. However, the temporal dissociation between motor signs such as mutism, posturing, staring, immobility, rigidity and autonomic signs such as tachycardia and hypertension allow distinction between NMS and PSH.…”
Section: Introductionmentioning
confidence: 99%